Last $29.01 USD
Change Today -0.15 / -0.51%
Volume 2.7K
CSII On Other Exchanges
As of 9:34 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

cardiovascular systems inc (CSII) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - $37.73
52 Week Low
10/1/14 - $23.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cardiovascular systems inc (CSII) Related Bloomberg News

View More Bloomberg News

cardiovascular systems inc (CSII) Related Businessweek News

No Related Businessweek News Found

cardiovascular systems inc (CSII) Details

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and markets devices for the treatment of vascular diseases. Its products include catheter-based platforms, such as the Stealth 360° Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Stealth 360° peripheral artery disease (PAD) System, Diamondback 360° PAD System, and Diamondback Predator 360° PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee. The company markets its products through direct sales force to hospitals and office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

479 Employees
Last Reported Date: 08/28/14
Founded in 1989

cardiovascular systems inc (CSII) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer
Total Annual Compensation: $330.7K
Chief Healthcare Policy Officer
Total Annual Compensation: $318.7K
Chief Administrative Officer, Compliance Offi...
Total Annual Compensation: $296.4K
Executive Vice President of Sales & Marketing
Total Annual Compensation: $305.4K
Compensation as of Fiscal Year 2014.

cardiovascular systems inc (CSII) Key Developments

Cardiovascular Systems Completes Coast Study Enrollment in Japan

Cardiovascular Systems Inc. announced that it has completed enrollment in Japan for its Coronary Orbital Atherectomy System Trial (COAST) study. Taking place in both Japan and the United States, the study is designed to assess the safety and efficacy, as well as economic outcomes, of CSI's new investigational micro crown Orbital Atherectomy System (OAS) in treating severely calcified coronary lesions in patients suffering from Coronary Artery Disease (CAD). COAST requires a minimum of 50 patients in the U.S. at up to 15 sites and a minimum of 25 patients across 5 sites in Japan for a total of 100 patients to be enrolled. CSI surpassed its required number of enrollments in Japan with a total of 26 patients on November 20, 2014. Enrollment in the United States is expected to be completed in 2015. The 1.25 mm micro crown is CSI's second-generation system designed to facilitate stent delivery in patients with severely calcified lesions who are acceptable candidates for percutaneous transluminal coronary angioplasty (PTCA) or stenting. The micro crown OAS is designed to improve the tracking and piloting of the OAS driveshaft and the ability of the crown to reach the lesion while operating at lower rotational speeds. COAST builds on CSI's ORBIT II study, the first trial designed to study patients with severely calcified lesions who are typically excluded from all major trials but commonly seen in the real world. It is a prospective, single-arm, multi-center, global, investigational study.

Cardiovascular Systems Inc. Receives CE Mark for Stealth 360(R) Peripheral Orbital Atherectomy System

Cardiovascular Systems Inc. (CSI) announced that it has received CE (Conformité Européenne) Mark for its Stealth 360 Orbital Atherectomy System (OAS). Stealth 360 is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD). Stealth 360 will be available in Europe with a 0.014" guide wire platform, and crown sizes of 1.25mm, 1.50mm, 1.75mm and 2.00mm. The system consists of the main components: Orbital Atherectomy Device, Saline Pump, Atherectomy guide wire and Atherectomy lubricant, all of which received CE Mark.

Cardiovascular Systems Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Provides Earnings Guidance for the Second Quarter Ending December 31, 2014

Cardiovascular Systems Inc. reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported revenue of $41,354,000 compared to $29,766,000 a year ago. Loss from operations was $8,190,000 compared to $6,847,000 a year ago. Net loss and comprehensive loss was $8,224,000 compared to $7,292,000 a year ago. Basic and diluted net loss per common share was $0.26 compared to $0.29 a year ago. Adjusted LBITDA was $4,209,000 compared to $4,231,000 a year ago. Net loss increased from the prior year as a result of planned investments, including $12.4 million of expenses related to coronary market launch initiatives, clinical studies and new product development. For the fiscal 2015 second quarter ending December 31, 2014, the company anticipates revenue growth of 33% to 39% over the second quarter of fiscal 2014, to a range of $43.1 million to $44.8 million. The company expects gross profit as a percentage of revenues similar to the first quarter of fiscal 2015. The company expects net loss in the range of $11.0 million to $12.0 million, or loss per common share ranging from $0.35 to $0.38.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSII:US $29.01 USD -0.15

CSII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $20.09 USD -0.128
CryoLife Inc $11.70 USD -0.04
Endologix Inc $14.53 USD +0.055
Spectranetics Corp/The $34.90 USD +0.25
Vascular Solutions Inc $28.79 USD -0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation CSII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOVASCULAR SYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at